Gilead Sciences Stock Intrinsic Value – Gilead Sciences: A Pharma Stock to Watch Amid Multiple ASCO Data Readouts

🌥️Trending News

Gilead Sciences ($NASDAQ:GILD), Inc. is an American biotechnology company that focuses on developing treatments for life-threatening diseases. In recent years, Gilead has become one of the most watched pharmaceutical stocks, as the company is set to release data points from multiple trials at the upcoming American Society of Clinical Oncology (ASCO) conference. With the success of their prior clinical trials and ongoing research, Gilead Sciences is an interesting stock to consider for investors. At the upcoming ASCO conference, Gilead is set to release data from trials that focus on a variety of diseases. For instance, the company will be sharing data related to their treatment for non-small cell lung cancer (NSCLC) and castration-resistant prostate cancer (CRPC).

Additionally, Gilead will also be presenting results from a Phase III trial for their systemic lupus erythematosus (SLE) treatment. With so many data points being unveiled at the conference, investors can expect to gain even more insight into the potential of Gilead’s treatments and the future of their stock. Given the amount of data points that will be revealed at ASCO and Gilead’s prior success in developing treatments, the company’s stock is certainly worth watching. With strong research and promising results from their clinical trials, Gilead Sciences is an interesting pharmaceutical stock to consider for investors.

Stock Price

Gilead Sciences is a pharmaceutical stock to watch as multiple data readouts from the American Society of Clinical Oncology (ASCO) are expected to be released in the coming weeks. On Wednesday, Gilead Sciences stock opened at $76.6 and closed at $76.9, representing a 0.8% increase from the previous closing price of $76.3. This marks the first positive swing for the stock in the past few weeks, which could be an indication of investor optimism surrounding the ASCO data readouts. It remains to be seen how Gilead Sciences will perform when the results of the readouts are made public, but investors should pay close attention to any major changes in the stock price that may occur. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for Gilead Sciences. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for Gilead Sciences. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for Gilead Sciences. More…

Key Ratios Snapshot

Some of the financial key ratios for Gilead Sciences are shown below. More…

Analysis – Gilead Sciences Stock Intrinsic Value

At GoodWhale, we recently conducted an analysis of Gilead Sciences‘ financials. Our proprietary Valuation Line indicates that the intrinsic value of GILEAD SCIENCES share is around $71.4. Currently, GILEAD SCIENCES stock is being traded at $76.9, making it slightly overvalued by 7.7%. We believe that this is a fair price, and the market is providing investors with an opportunity to invest in the company. We are optimistic that Gilead Sciences will continue to grow and create value for investors in the long-term. More…

Peers

In the biopharmaceutical industry, competition is fierce. Among the companies vying for market share are Gilead Sciences Inc, Eli Lilly and Co, Amgen Inc, and SCYNEXIS Inc. All of these companies are working to develop new and innovative treatments for a variety of diseases.

– Eli Lilly and Co ($NYSE:LLY)

Eli Lilly and Co is a pharmaceutical company with a market cap of 316.8 billion as of May 2021. The company has a return on equity of 45.88% and is headquartered in Indianapolis, Indiana. Eli Lilly and Co develops and markets prescription medications and over-the-counter products. The company’s products are available in approximately 120 countries.

– Amgen Inc ($NASDAQ:AMGN)

Amgen Inc is a biopharmaceutical company with a market cap of 135.3B as of 2022. The company has a return on equity of 460.37%. Amgen Inc is a biopharmaceutical company that discovers, develops, manufactures, and delivers human therapeutics worldwide. The company offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and nephrology.

– SCYNEXIS Inc ($NASDAQ:SCYX)

SCYNEXIS Inc. is a biopharmaceutical company, which focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. The company’s lead product, SCY-078, is an oral and intravenous antifungal agent in Phase 3 clinical development for the treatment of serious and life-threatening invasive fungal infections. SCYNEXIS Inc. was founded by Peter R. Lupton, David P. Lupton and George W. Schmidt in December 1997 and is headquartered in Durham, NC.

Summary

Gilead Sciences is an attractive investment for those looking to capitalize on upcoming ASCO data readouts. The biopharmaceuticals giant has a broad portfolio of drugs and is well-positioned to benefit from several potential breakthroughs in the near future. Its products are focused on areas such as HIV/AIDS, liver diseases, respiratory illnesses, and cancer.

In addition, Gilead has a strong balance sheet and a solid situation in terms of cash and cash equivalents. With strong fundamentals and an imminent influx of new drug data, the company is a favorable investment option. Furthermore, Gilead has sought to diversify its research and development efforts in order to increase its pipeline of new drugs, making it a smart choice for investors.